A clinical study of DKN-01 in combination with KEYTRUDA® (pembrolizumab) in patients with relapsed or refractory advanced esophagogastric cancers.
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs DKN 01 (Primary) ; Pembrolizumab
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 28 Jun 2017 New trial record
- 21 Jun 2017 According to a Leap Therapeutics media release, this study is expected to begin enrolling patients in the second-half of 2017.